Intraperitoneal and systemic chemotherapy for advanced endometrial adenocarcinoma: A case report

✍ Scribed by Vaughn, Clarence B. ;Chapman, Janet L. ;Herschman, Barry R. ;Bonczak, Michael J. ;Treisman, Edward J. ;Groshko, Gayle A. ;Nirenberg, Pauline L.

• Publisher: John Wiley and Sons
• Year: 1990
• Tongue: English
• Weight: 414 KB
• Volume: 18
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/mpo.2950180115

✦ Synopsis

Abstract

Five to ten percent of patients with adenocarcinoma of the endometrium present with advanced disease [1] or develop metastasis and require systemic therapy for control of disease. About one‐third (33%) of recurrent or advanced endometrial cancer responds to progestational agents [2–4]. The efficacy of a single chemotherapeutic agent in endometrial adenocarcinoma is in the range of 20–30% [5–7]. Multidrug programs have produced a response rate between 30% to 70% in advanced cancer of the endometrium [8–12]. Knapp et al. [13] and Esposito et al. [14] reported that the intraperitoneal route of chemotherapy administration produced peak concentration of the drug in the abdomen that was 30–400 times that attained by the intravenous route. This case report illustrates a favorable response in advanced endometrial adenocarcinoma to a multiagent program consisting of intraperitoneal administration of two agents and an oral progestational agent.